Azole Antifungal Consumption in Community Pharmacy Sales in Mainland Portugal: Trend Analysis from 2014 to 2023
- PMID: 39858319
- PMCID: PMC11760455
- DOI: 10.3390/antibiotics14010033
Azole Antifungal Consumption in Community Pharmacy Sales in Mainland Portugal: Trend Analysis from 2014 to 2023
Abstract
Background/Objectives: Excessive or inadequate use of antimicrobial drugs may lead to the emergence of resistant strains. For this reason, it is important to monitor consumption indicators to assess drugs' utilization over time. This study aimed to analyze the consumption of medically prescribed azole antifungal drugs in mainland Portugal from 2014 to 2023, focusing on those directed to genital infections: fluconazole, isoconazole, itraconazole, and sertaconazole. Methods: For each drug, the evaluated parameters were the total number of packages, number of packages per 1000 inhabitants, defined daily dose (DDD) per 1000 inhabitants per day, and total costs. For this purpose, we used data from community pharmacies' sales, which are available through INFARMED (the Portuguese national authority on medicines and health products). Results: Several trends emerged from data analysis. The COVID-19 pandemic negatively affected the consumption of all azole antifungal drugs included in this study. However, after 2020, fluconazole and sertaconazole consumption has been increasing. In the specific case of fluconazole, there was an increase in expenditure, although the total number of packages suffered a decrease over the 10-year study period. Additionally, the defined daily dose (DDD) per 1000 inhabitants per day for fluconazole and itraconazole was lower compared to estimates from the last available survey (2009). Conclusions: Although our findings represent a lesser pressure on fungi, further monitoring is needed to better understand the evolution of fluconazole and itraconazole consumption over time, particularly due to the trends observed in this study.
Keywords: Portugal; fluconazole; isoconazole; itraconozole; sertaconazole.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study.Lancet Psychiatry. 2021 Dec;8(12):1071-1082. doi: 10.1016/S2215-0366(21)00292-3. Lancet Psychiatry. 2021. PMID: 34801129 Free PMC article.
-
Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: I. Analyses of a unique database.Infect Dis Obstet Gynecol. 2004 Jun;12(2):91-7. doi: 10.1080/10647440400003873. Infect Dis Obstet Gynecol. 2004. PMID: 15739823 Free PMC article.
-
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries.Drugs. 2022 Jul;82(11):1193-1205. doi: 10.1007/s40265-022-01751-x. Epub 2022 Aug 12. Drugs. 2022. PMID: 35960433 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Antifungal drug resistance in pathogenic fungi.Med Mycol. 1998;36 Suppl 1:119-28. Med Mycol. 1998. PMID: 9988500 Review.
References
-
- World Health Organization . WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. World Health Organization; Geneva, Switzerland: 2022.
-
- Fisher M.C., Alastruey-Izquierdo A., Berman J., Bicanic T., Bignell E.M., Bowyer P., Bromley M., Brüggemann R., Garber G., Cornely O.A., et al. Tackling the emerging threat of antifungal resistance to human health. Nat. Rev. Microbiol. 2022;20:557–571. doi: 10.1038/s41579-022-00720-1. - DOI - PMC - PubMed
-
- World Health Organization . Web Annex A. World Health Organization Model List of Essential Medicines–23rd List, 2023. World Health Organization; Geneva, Switzerland: 2023.
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials